Co-Authors
This is a "connection" page, showing publications co-authored by Barney Graham and Peter Kwong.
Connection Strength
2.081
-
Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines (Basel). 2021 Jan 21; 9(2).
Score: 0.231
-
A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci Rep. 2020 10 23; 10(1):18149.
Score: 0.227
-
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020 10 27; 33(4):108322.
Score: 0.227
-
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
Score: 0.224
-
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat Immunol. 2019 Jun; 20(6):765.
Score: 0.206
-
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018 05 15; 92(10).
Score: 0.191
-
Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. ACS Infect Dis. 2018 05 11; 4(5):788-796.
Score: 0.189
-
Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015 Jul 28; 6:7712.
Score: 0.158
-
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med. 2021 08 18; 13(607).
Score: 0.060
-
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
Score: 0.060
-
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 08 05; 184(16):4203-4219.e32.
Score: 0.059
-
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 05; 593(7857):130-135.
Score: 0.058
-
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 2019 10; 6(10):e667-e679.
Score: 0.052
-
Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F. J Virol. 2017 11 15; 91(22).
Score: 0.046
-
Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol. 2017 Jul 14; 2(13).
Score: 0.045
-
Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. J Virol. 2017 08 01; 91(15).
Score: 0.045